The 2026 Healthtech Messaging Index

Rank#94of 302

Proscia

proscia.com·scored November 1, 2026

61out of 100

23/38

Approaching

Close. The bones are good. A few targeted fixes on the weakest signals would push Proscia into magnetic territory.

ApproachingAI recommends them? Yes
Proscia homepage

The page we scored

The AI Recommendation Check

When we asked AI who to recommend for Digital pathology platform and AI software for clinical and life sciences, it named:

Buyer we put in the prompt: Pathologist, lab director, or digital pathology leader at a hospital, clinical lab, or top-20 pharmaceutical company. Both the buyer and the category were inferred from Proscia’s homepage alone. The model had no web access.

Philips Digital PathologyLeica Biosystems (Aperio)Hamamatsu (NDP)Paige AIPathAIVisiopharmSectra

Proscia was on the list.

AI named them for their own category. That's the signal every homepage is supposed to send.

AI mentioned you for "Digital pathology platform and AI software for clinical and life sciences", but only generically: "Proscia offers the Concentriq digital pathology platform aimed at both clinical and biopharma customers, with a focus on AI-enabled workflows and image management.". You're on the radar, but AI doesn't yet repeat your specific positioning back.

Overall assessment

Proscia's biggest strength is its proof density ... specific stats (12M cases, 100% KLAS repurchase intent, 16 of top 20 pharma), named testimonials with titles, and third-party KLAS #1 recognition give it unusually strong trust signals for a B2B homepage. The biggest gap is the complete absence of problem leadership and cost-of-inaction framing: the page never articulates what is broken in legacy pathology workflows or what a buyer loses by waiting, which means Proscia is selling the destination without acknowledging the pain that makes buyers move.

Signal by category

Narrative Clarity

8 signals

8/16

Trust Signal

4 signals

6/8

AI Signal

6 signals

8/12

Conversion Signal

1 signal

1/2
0

Weakest signal · fix this first

05Problem Leadership

“No problem statement in buyer language; page opens with "Intelligence for the Decisions that Matter Most.”

The hero leads entirely with an aspirational product frame, not with the buyer's pain ... there is no articulation of what is broken, slow, or costly before the solution is presented.

All 19 signals, scored 0 to 2.

Narrative Clarity

8 signals

8/16
  • 01The 7-Second Test

    “Intelligence for the Decisions that Matter Most" / "Pathology's AI platform for the experts answering medicine's biggest questions”

    The vertical (pathology) and audience (pathology experts) are decipherable in 7 seconds, but 'decisions that matter most' is vague aspiration ... a caveman cannot immediately grasp the concrete problem being solved.

    1
  • 02Rebellion / Movement

    “The hardest part of going digital isn't the technology.”

    There's a hint of rebellion against the idea that digital transformation is purely a tech problem, but no named enemy, no named status quo (e.g., analog slide review, legacy LIS), and no explicit movement the company is leading.

    1
  • 03Owned Language & Category

    “Concentriq" / "Aperture network" / "Pathology AI for Precision Medicine" / "Feats of Strength”

    Proscia owns the branded platform name Concentriq, the Aperture network, a named video series (Feats of Strength), and frames 'computational pathology' as a distinct category ... enough proprietary language for an AI to quote back distinctively.

    2
  • 04ICP Clarity

    “Clinical LAB SOLUTIONS" / "Life Sciences SOLUTIONS" / "16 of the top 20 pharma companies and over 4,000 hospitals and clinics globally”

    The page clearly segments two ICPs ... clinical pathology labs and biopharma/life sciences ... with named institutions, making it easy for the right buyer to self-identify.

    2
  • 05Problem Leadershipweakest

    “No problem statement in buyer language; page opens with "Intelligence for the Decisions that Matter Most.”

    The hero leads entirely with an aspirational product frame, not with the buyer's pain ... there is no articulation of what is broken, slow, or costly before the solution is presented.

    0
  • 06Solution Clarity

    “The Concentriq portfolio powers precision medicine from discovery through diagnosis, with purpose-built solutions for biomarker research, clinical trials, companion diagnostics, and case review.”

    A visitor can roughly understand what Proscia does, but 'powers precision medicine' is still abstract ... the sentence lists use cases without explaining the mechanism, so repeatability is partial.

    1
  • 07Cost of Inaction

    “No mention of cost of delay, missed diagnoses, failed trials, or any consequence of not adopting digital pathology.”

    The page never names what a pathology lab or pharma company loses by staying on legacy workflows ... stakes are completely absent.

    0
  • 08Promised Land

    “Turn tissue into biomarker insights, move therapies through development and get them to the patients who need them.”

    There is an implied 'after' state ... therapies reaching patients faster ... but it's expressed as a tagline, not a vivid, specific promised land with concrete outcomes the buyer will experience.

    1

Trust Signal

4 signals

6/8
  • 09Proof & Evidence

    “12M cases managed annually" / "4,000+ hospitals and clinics" / "30,000+ studies powered" / "100% of customers told KLAS they would buy Concentriq again”

    Multiple concrete, specific numbers anchor the proof section, including a striking 100% KLAS repurchase intent stat that is outcome-adjacent and credible.

    2
  • 10Social Proof

    “Dr. Luis Cano, Dr. Cherub Kim (Labcorp), Dr. Amanda Hemmerich (IQVIA Laboratories), Dr. Derrick Forchetti (South Bend Medical Foundation)”

    Named testimonials with full title, employer, and photos appear alongside major logo-wall clients like Bayer, Cleveland Clinic, Bristol Myers Squibb ... social proof is strong and specific.

    2
  • 11Authority & Credibility

    “Best in KLAS 2026" / "Concentriq is the highest-rated digital pathology platform in both the United States and Europe”

    Third-party KLAS recognition with a #1 ranking in two geographies is demonstrated authority, not self-claimed, and is prominently featured with a linked report.

    2
  • 12Alternatives Acknowledged

    “No mention of competitors, alternative approaches, or the 'do nothing' option anywhere on the page.”

    Alternatives are entirely unacknowledged ... no competitive framing, no 'vs. traditional slide review,' no honest engagement with why a buyer might not change.

    0

AI Signal

6 signals

8/12
  • 13Customer Focus

    “Feats of Strength tells their stories" / customer testimonial section centers on pathologist champions”

    The Feats of Strength section genuinely centers customers, but the hero, platform section, and stats sections tilt back toward Proscia's capabilities and scale ... making it a mixed narrative.

    1
  • 14AI-Parmesan Index

    “Pathology's AI platform" / "Pathology AI for Precision Medicine" / "computational pathology is essential”

    AI is central to positioning but the page doesn't explain the mechanism ... how the AI works, what models do, what makes it different ... leaving the claims at marketing-label level rather than substantive specificity.

    1
  • 15LLM Quotability

    “16 of the top 20 pharma companies run on Concentriq" / "100% of customers told KLAS they would buy Concentriq again" / "Best in KLAS 2026”

    Several declarative, citation-ready sentences with specific numbers and named third-party validation exist that an LLM could lift verbatim to recommend Proscia in a comparison query.

    2
  • 16Copyright Freshness

    “Best in KLAS 2026" / Blog and webinar content visible but no explicit publication dates shown in the scraped content.”

    The KLAS 2026 reference signals currency, but no explicit dates on blog posts or press releases appear in the scraped content, so recency signaling is incomplete.

    1
  • 17Entity Distinctiveness

    “Concentriq" / "Aperture network" / "16 of the top 20 pharma companies" / "Best in KLAS 2026 in both the United States and Europe”

    The combination of a proprietary platform name, a named network, KLAS #1 in two geographies, and dual clinical/life-sciences segmentation makes Proscia distinctly identifiable ... an AI could not easily attribute this profile to a generic competitor.

    2
  • 18AI Recommendation Check

    “AI named you alongside Philips Digital Pathology, Leica Biosystems (Aperio), Hamamatsu (NDP), Paige AI, PathAI, describing you as: "Proscia offers the Concentriq digital pathology platform aimed at both clinical and biopharma customers, with a focus on AI-enabled workflows and image management.".”

    AI mentioned you for "Digital pathology platform and AI software for clinical and life sciences", but only generically: "Proscia offers the Concentriq digital pathology platform aimed at both clinical and biopharma customers, with a focus on AI-enabled workflows and image management.". You're on the radar, but AI doesn't yet repeat your specific positioning back.

    1

Conversion Signal

1 signal

1/2
  • 19Path & CTA Clarity

    “EXPLORE CONCENTRIQ" / "READ THE KLAS REPORT" / "SEE THEIR STORIES" / "Save my spot”

    There are multiple CTAs but no single dominant primary CTA, no soft secondary clearly paired to it, and no numbered process path ... the page offers a menu of actions rather than a guided conversion funnel.

    1

Keep the lead

AI already names Proscia. The next edition decides if it still does.

Twenty minutes with Greg. Bring the page, bring the argument. You’ll leave knowing exactly which signal is costing Proscia the AI recommendation, and what to write instead.

Not on the list? Run your homepage through the free Brand Signal Score and see where you’d land. Same 19 signals, same AI check, two minutes.

← Back to the full Healthtech index

We revamp websites that ChatGPT ignores.

See the 90-Day AI Website Rebuild →